RQ Biotechnology Ltd.

RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The Company is advancing its lead product RQB01, a long-acting, potent and broadly protective antibody product, through IND-enabling studies.

Founded in 2021, RQ Bio has a highly experienced team with proven success in developing long-acting antibodies against viral targets. RQ Bio is backed by a strong syndicate of investors – Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, and LifeArc Ventures as well as Oxford Science Enterprises and the University of Oxford.